OPR - Delayed Quote • USD ALLK Sep 2024 2.500 call (ALLK240920C00002500) Follow 0.1000 0.0000 (0.00%) As of April 23 at 11:21 AM EDT. Market Open. Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for ALLK240920C00002500 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: ALLK 3 Biotech Stocks to Dump Before They Go to Zero Allakos (ALLK): Strong Industry, Solid Earnings Estimate Revisions Allakos Inc (ALLK) Reports Increased R&D Expenses and Net Loss in Q4 Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024 Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition Biotech Stock Roundup: VRTX/CRSP Gene Therapy Label Expansion, ALLK Falls on Update Here's Why Allakos Inc. (ALLK) is Poised for a Turnaround After Losing -61.36% in 4 Weeks Allakos (ALLK) Plummets 60% on Ending Development of Lead Drug Is Allakos (ALLK) Stock Outpacing Its Medical Peers This Year? UPDATE 2-Allakos tumbles after skin disease drug fails mid-stage studies Allakos Announces a Restructuring to Focus on Development of AK006
